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Summary 
The aim of this work was to characterise staphylococcal bacteriophage (a 
bacterial virus) and to assess their potential as therapeutic agents against pathogenic 
strains of Staphylococcus aureus, particularly mastitis-causing strains.  The project 
included the use of two newly isolated phage CS1 and DW2, and an existing 
polyvalent phage.  The new phage were isolated from the farmyard and characterised 
by electron microscopy and restriction analysis.  Both phage were shown to belong to 
the Siphoviridae family and were lytic for representatives of all three clonal groups of 
Irish mastitis-associated staphylococci.  A cocktail of three phage (CS1, DW2 and K) 
at 108 (plaque forming units) PFU/ml was infused into cows teats in animal trials.  
The lack of an increase in somatic cell counts in milks indicated strongly that the 
phage did not irritate the animal.  In addition, the most potent phage used in this 
study, phage K, was further studied by genome sequencing, which revealed a linear 
DNA genome of 127,395 base pairs, which encodes 118 putative ORFs (open reading 
frames).  Interesting features of the genome include; 1) a region exhibiting high 
homology to the structural module from Listeria phage A511, 2) genes which 
potentially encodes proteins necessary for its own replisome, 3) an absence of GATC 
sites and 4) three introns encoding putative endonucleases were located in the 
genome, (two in the putative DNA polymerase gene and one in the lysin gene).  
Unlike both CS1 and DW2, the polyvalent phage K, exhibited a broad host range 
within the genus Staphylococcus.  In in vitro inhibitory assays, phage K lysed all 
staphylococcal strains tested including nine different species.  In preliminary 
application-type studies, anti-staphylococcal activity was also evident in a hand wash 
Project 4942 
 2 
and phage cream.  An unexpected result was the observation that phage K was unable 
to replicate in raw milk, which could limit its applications in mastitis treatments.  This 
may have been due to clumping of the bacteria caused by immunoglobulins.  
However, inhibition activity was lost after milk was heat-treated. The overall results 
in this study provide new insights into the biology of the broad host range phage K 
and indicate that phage K has potential for treatment and prevention of infections 
caused by pathogenic staphylococci. 
 
Introduction  
The prevalence of antibiotic resistance in the pathogen Staphylococcus aureus 
is a major problem, given that the bacterium causes a wide variety of human and 
animal infections.  Infections in humans caused by S. aureus include primary 
infections such as osteomyelitis, impetigo, septicaemia, and secondary infections such 
as eczema and decubitus ulcers (Noble 1998).  Mastitis in dairy cattle is the most 
common cause of death in adult dairy cows (Bradley 2002) causing estimated losses 
worldwide of 35 billion US dollars annually (Wellenberg et al. 2002).  Staphylococcal 
mastitis, in particular, can be manifested by clinical and subclinical infection that can 
persist throughout the lactation period and into subsequent lactations (Kerro Dego et 
al. 2002).  Such infections are generally not treated satisfactorily by antibiotic therapy 
in eliminating existing disease or in preventing the establishment of chronic infection 
(Sol et al. 2000; Kerro Dego et al. 2002).  The pathogenic potential of Staphylococcus 
is greatly aided by its ability to develop resistance to antibiotics (Lowy 2003). Indeed, 
more than 90% of strains are now believed to be penicillin resistant (Rubin et al. 
1999) and consequently methicillin has become one of the drugs of choice for treating 
infections.  However, the emergence of methicillin resistant Staphylococcus aureus 
(MRSA) (Lowy 2003) has led to the use of vancomycin to treat these MRSA strains. 
Therefore, the more recent reports of vancomycin resistant S. aureus (VRSA) strains 
are of obvious concern (Lowy 2003).   
Investigations for new and alternative anti-microbials effective against S. 
aureus have become increasingly relevant for both human and veterinary applications. 
Bacteriophage (phage) are obligate intracellular parasites that multiply inside bacteria 
and in so doing make use of the host biosynthetic machinery.  Phage come in many 
shapes and sizes and have either DNA or RNA as their genetic material.  This DNA 
or RNA genome is encapsulated in a protein coat, which is normally connected to a 
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base-plate by a tail.  Phage were investigated to eliminate bacteria as far back as 1921, 
including staphylococci in human infections (Chanishvili et al. 2001).  The aim of this 
project was to characterise staphylococcal bacteriophage and to evaluate their 
potential as therapeutic agents against pathogenic strains of Staphylococcus aureus.   
 
1. Isolation and characterisation of two anti-staphylococcal bacteriophages 
specific for pathogenic Staphylococcus aureus associated with bovine infections 
 
Summary 
We describe the isolation of two anti-staphylococcal phage (viruses which 
infect S. aureus) namely DW2 and CS1 from farmyard slurry using the strain 
DPC5246.  Both phage were characterised by electron microscopy and restriction 
analysis and shown to belong to the Siphoviridae family. CS1 and DW2 were lytic for 
representatives of all three clonal groups of Irish mastitis-associated staphylococci.  
Infection of S. aureus DPC5246 (106 (colony forming units) CFU ml-1) with CS1 and 
DW2 alone or in combination resulted in kill rates of 99.5%. A cocktail of three 
phage (CS1, DW2 and K) at 108 PFU /ml was infused into cow’s teats in animal trials.  
The observation that there was no detectable increase in somatic cell counts (SCCs) in 
milks indicates that the phage did not irritate the mammary tissue.  
 
Results  
Selection of Staphylococcus aureus host strains for phage isolation 
S. aureus isolates from bovine mastitis infections in Ireland were previously 
divided into three major clonal/RAPD (Randomly amplified polymorphic DNA) 
groups, namely RAPD group 5, 7 and 4 (Fitzgerald et al. 1997), with a representative 
strain for each group classified as DPC5245, DPC5246 and DPC5247, respectively 
(Twomey et al. 2000).  S. aureus DPC5246 was used for the initial screening of 
environmental samples for phage. It was later found that phage which were identified 
using this strain could also form plaques on strains DPC5245 and DPC5247. 
 
Isolation of wild-type phage from farmyard slurry  
Twenty farmyard slurry samples from a variety of locations in different farms 
were screened for the presence of phage, which were capable of forming plaques on 
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strain S. aureus DPC5246. Five samples gave positive results, in that non-turbid 
plaques were visible in lawns of strain DPC5246. These plaques were isolated and 
propagated on strain DPC5246 allowing the extraction of phage DNA from each 
phage for restriction analysis.  Restriction endonucleases, which gave clear digests 
included XbaI and XhoI, (Fig. 1b). Comparison of restriction digests indicated that 
there were only two distinct phage as evidenced by the XbaI digests shown in Figure 
1. These were designated DW2 and CS1.  Three of the phage gave identical patterns 
to either DW2 or CS1 and thus these three were excluded from the study. The 
previously characterised phage K was included in the restriction analysis for 
comparison. Different restriction patterns were observed for each phage, CS1 and 
DW2, when compared to phage K (Fig. 1b, lane 2, 4 and 6), whereas, restriction 
patterns of phage CS1 and DW2 had some similarities indicating that both phage are 
related at the genetic level (Fig. 1b).  
 
Characterization of phage CS1 and DW2 
The plaque-forming ability of phage CS1 and DW2 were compared. Phage 
CS1 and DW2 formed clear plaques of 1 mm in diameter on strain DPC5246.  
Morphological analysis of phage DW2 and CS1 by electron microscopy (Fig. 1) 
allowed each to be classified into its respective viral family and order.  Both phage 
have an obvious tail and hence belong to the order Caudovirales.  Phage CS1 has a 
non-contractile flexible tail 112.5 +/- 2.5 nm in length and an isometric head 40.8 +/- 
3.8 nm in diameter, a base plate extending from the end of the tail can also be 
observed (Fig. 1, i).  DW2 has a similar morphology to CS1 with a long flexible tail 
120 +/- 10 nm in length and an isometric head 39.8 +/- 0.76 nm in diameter (Fig. 1, 
ii).  Both CS1 and DW2 can therefore be classified into the Siphoviridae family based 
on guidelines of the International Committee on Taxonomy of Viruses (Murphy 
1995).  
 
Bacteriophage host range  
The potential efficacy of CS1 and DW2 to be used in combination with phage 
K was studied in a cocktail for control of bovine mastitis staphylococci.  The host 
range of CS1 and DW2 were therefore assessed and compared to that of phage K. 
Both CS1 and DW2 were found to lyse the representatives of the three groups of 
bovine S. aureus isolates.  In addition, a number of human S. aureus isolates were 
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also included to help establish the extent of the host range (Table 1).  These strains are 
MRSA isolates, which were previously sourced from human infections in Irish 
hospitals and previously shown to be distinct from each other (Cotter et al. 1998).  
Details of the bacterial strains are shown in Table 1.  The host range of phage CS1 
and DW2 while not identical are similar with both phage capable of lysing some of 
the human strains.  In contrast, phage K lysed all strains tested.  Phage DW2 lysed the 
three bovine clonal types and their plaquing ability on these strains was quantified in 
terms of EOP (efficiency of plaquing) values.  The results demonstrate that DW2 
plaqued on DPC5246 (the propagating strain) with an EOP of 1.0, on DPC5245 with 
an EOP of 1.3 x 10-4 and on DPC5247 with and EOP of 7.6 x 10-2. It is expected that 
if DPC5245 or DPC5247 were used as the propagating strain, the EOP data would 
vary accordingly (Coffey and Ross 2002).  This phage was only weakly lytic against 
the human strains in that it did not form discernable plaques on these human strains 
although there was inhibition of bacterial growth on the lower dilutions of the plaque 
assay and also lysis by the spot test technique.  In the case of phage CS1, it plaqued 
on DPC5246 (the propagating strain) with an EOP of 1.0, on strain DPC5245 with an 
EOP of 6.0 x 10-3 and on DPC5247 with an EOP of 2.7 x 10-1.  This phage, like phage 
DW2 is also weakly lytic against the human-derived strains. The EOP data above 
suggests that strain DPC5245 possesses restriction modification activity (Coffey and 
Ross 2002) against CS1 and DW2 phage.  
 
Bacterial challenge tests 
Both phage CS1 and DW2 were assessed for their ability to lyse the mastitis 
causing-staphylococcal strain DPC5246 alone and in combination.  Lysis of strain 
DPC5246 was monitored by plate count in triplicate.  Each phage and a combination 
of CS1 and DW2 was added at a MOI of 10 to a mid-exponential culture of S. aureus 
DPC5246 at 37ºC.  At this point the culture was at a concentration of approximately 
106 CFU ml-1.  Three hours after phage addition, regardless of whether a single phage 
or both in combination was added, the bacterial numbers were reduced 10,000-fold (4 
logs) when compared to the control where no phage had been added (Fig. 2). Thus, 
the combination of CS1 and DW2 did not increase the killing effect over and above 
either when used singularly (Fig. 2).  
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Potential of phage to irritate bovine mammary tissue 
A 10 mM sodium phosphate medium (pH 7) was employed as a carrier 
medium for infusion of phage in the bovine mammary gland.  When 100 µl of the 
carrier medium without phage was infused into the teat sinus, no increase in the 
somatic cell count (SCC) was observed in milks obtained in subsequent milkings 
indicating no immune response.  Following this, the carrier medium was used to 
deliver a cocktail of the three phage (CS1, DW2 and K, titer 108 PFU /ml) together 
also in a volume of 100 µl into the teat sinus.  This also resulted in no significant 
increase in the SCC.  SCCs of 1.83 x 105 were recorded in the test teat (right front) 
whereas, the SCC in the non-infused 3 control teats were 1.93 x 105, 1.81 x 105 and 
7.9 x 104, respectively in the four milkings taken during the two days post-infusion.  
This clearly indicates that high-titre phage preparations do not induce a local immune 
response and are therefore non-irritating to the animal. 
 
Discussion and Conclusions 
This study identified two new phage against bovine staphylococci, which were 
isolated from farmyard slurry against the bovine strain DPC5246, which is a 
representative of one of the three major clonal types that cause S. aureus mastitis in 
Ireland.  Phage CS1 and DW2 were assigned to the Siphoviridae family based on 
morphology.  Both phage were capable of forming plaques on the bovine strains, 
whereas, no discernable plaques were found against the human strains.  The two 
phage CS1 and DW2 were each capable of reducing staphylococcal counts 10,000 
fold at an MOI (multiplicity of infection) of 10.  The inclusion of the polyvalent 
phage K enhanced the anti-bacterial effect.  We showed that infusion of the phage 
cocktail into the bovine udder did not cause the SCC to rise above 400,000 /ml, 
indicating that there was no local immune response to high numbers of phage. In 
conclusion, we have identified two new phage against bovine staphylococci, which 
may be combined with anti-staphylococcal phage K.  This study confirms that the 
application of phage to the udder at high titer does not pose an irritation problem for 
the animal.  It thus opens the way for the incorporation of phage into teat-dips or teat-
washes as a prophylactic against bovine staphylococci which may naturally reside on 





2.  Inhibition of phage proliferation in raw bovine milk 
 
Summary 
The ability of bacteriophage (phage) to replicate in milk is important in 
situations where phage might be used as a therapeutic for bovine mastitis. Phage K 
was able to replicate normally, leading to the elimination of the host culture in milk, 
which had been previously heat-treated. When raw milk was used under identical 
conditions, the phage were unable to replicate. Phage adsorption assays were 
performed and these demonstrated that adsorption of phage was significantly reduced 
in the raw milk while it was restored in the heat-treated sample (86.5% compared to 
99.96% adsorption, respectively). When confocal microscopy with a LIVE/DEAD 
Baclight staining system was employed, it was observed that in raw milk S. aureus 
formed clusters associated with fat globules, while in heat-treated milk, bacterial 
agglutination had not occurred. 
 
Results and Discussion 
Staphylococcal phage inhibition in raw milk and dry cow secretion 
The lytic activity of phage K was examined in detail using S. aureus 
DPC5645. Growth of this bacterium was therefore measured by plate count in BHI 
broth, HT milk, raw milk and dry cow secretion. Phage was added 4 h after bacterial 
inoculation. In the case of BHI and HT milk, the bacterial numbers declined to 
undetectable levels within 2 h. In the case of the raw milk and the dry-cow secretion, 
there was no detectable reduction in bacterial numbers (Fig. 3).  
To explain the inhibition of the phage activity in the raw milk and dry-cow 
secretion, bacterial adsorption tests were performed and the results compared for raw 
milk and HT milk. Essentially, free phage numbers were assessed 15 min after 
addition of phage to milks containing S. aureus DPC5246. It was observed that there 
were far higher numbers of free phage present in the raw milk supernatant compared 
to the HT milk supernatant indicating that the phage adsorption process was being 
inhibited in the raw milk. Indeed, 99.96% of phage K was adsorbed by S. aureus 
DPC5246 in HT milk compared to 86.5% of phage in raw milk, which represents a 
1,000 fold decrease of adsorption in raw milk.   These results suggest that some heat-
sensitive component in the raw milk is preventing the adsorption of phage to cells and 
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it also indicates that the phage particles themselves are not being inactivated given 
that they are still capable of plaquing during the plaque assay stage of the adsorption 
test. The phage inhibitor is thus likely to be associated with the bacterial cells 
themselves. 
 
In situ staining of S. aureus DPC5246 
In situ LIVE/DEAD BacLight stain which shows red fluorescence for dead 
bacteria and green fluorescence for living bacteria was employed with Confocal 
Scanning Laser Microscopy (CSLM) for analysing the behaviour of S. aureus 
DPC5246 in raw and HT milk before and 60 min after addition of staphylococcal 
phage K. In the case of the raw milk, staphylococcal cells were organised in clumps 
and all cells were alive (Fig. 4a). After addition of phage K, the majority of 
staphylococci in the clump were still alive, although one or two dead cells are evident 
within some of the clumps (Fig. 4b). In the case of the HT milk, staphylococcal cell 
clumping was not evident as the cells were distributed throughout the sample (Fig 4c). 
One hour after addition of phage K, it was difficult to locate cells within the sample 
and any intact bacterial cells that were visualised were stained red and were thus dead 
(Fig. 4d). These results correlate with the cell counts during phage challenge in the 
different milks.  Cell clumping is known to be due to the action of immunoglobulins 
of the M class or agglutinins in the raw milk and this activity is heat sensitive 
(Walstra and Jenness 1984) and also that some bacterial species are more sensitive to 
this immunoglobulin activity than others. It would, appear therefore that the phage 
resistance is not necessarily due to the clumping per se, but alternatively could be 
connected to immunoglobulins coating the bacterial cell surface and preventing 
adsorption of bacteriophage.  
 
Phage challenges in homogenised milk and whey 
 Examination of S. aureus DPC5246 by CSLM, clearly indicated cell 
agglutination (Fig. 4a). Many of these clumps appeared to be associated with fat 
globules and it has also been reported that immunoglobulins bind bacteria to fat 
globules (Walstra and Jenness 1984). Challenges were performed in homogenised 
milk to investigate if the fat globules in raw milk were responsible for the reduced 
phage activity. Raw milk was homogenised and a phage challenge was performed in 
the homogenised sample. During the homogenisation protocol milk was heated to 
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45°C prior to homogenisation; hence, a control challenge was also performed in milk 
heated to 45°C. The inability of phage K to inhibit DPC5645 at 45°C indicated that 
the protein inhibiting phage adsorption was still functional after heat treatment at this 
temperature.  It was found that homogenisation of the milk did not greatly improve 
the phage activity against staphylococci in the raw milk. Assays were also performed 
in whey, the aqueous fraction of milk remaining after the removal of fat and casein. 
As with the above assays, phage proliferation in heated and unheated whey was 
tested. In the HT whey phage K reduced bacterial numbers to undetectable levels 
within 2 h. In contrast, when the whey was unheated, phage K activity was inhibited, 
but not completely inhibited as seen in the raw milk. In this case, the phage did reduce 
the bacterial numbers to undetectable levels within 4 hours. Therefore inhibition of 
phage activity is still present in the whey, but it appears that the removal of the fat and 
various other milk proteins during whey production has reduced the effect. 
 
Conclusions  
Bacteriophage K is a candidate phage for therapeutic applications both for 
humans and animals. The phage has previously been included in washes to reduce 
numbers of staphylococci (O'Flaherty et al. 2005). In addition, we explored its 
infusion into bovine teats for mastitis control. In this context, the efficacy of the phage 
was examined in dry-cow secretions and also in raw milk. It was consistently 
observed that the phage killing effect disappeared in both of these media. In 
conclusion, investigation of phage K activity in raw bovine milk shows that the host 
bacterium for the phage is organised into clumps due to agglutinins active in the raw 
milk. The ability of phage K to lyse these bacteria is inhibited, unless the milk is 
heated. It is likely therefore, that heat-labile immunoglobulins, which recognise and 
bind to the bacterial cell surface, are responsible for this effect. Thus, the use of phage 
to eliminate these pathogens, which are recognised by these milk immunoglobulins, 







3. Potential of the polyvalent anti-Staphylococcus bacteriophage K for the 
control of antibiotic-resistant staphylococci. 
 
Summary 
In this study, phage K was assessed in vitro for its ability to inhibit emerging 
drug resistant Staphylococcus aureus strains from hospitals and other species of 
Staphylococcus isolated from bovine infections. In in vitro inhibitory assays, phage K 
lysed a range of methicillin-resistant S. aureus (MRSA) strains, S. aureus with 
heterogeneous-vancomycin and vancomycin resistance as well as teicoplanin resistant 
strains. In these assays, 14 of the MRSA strains were initially only weakly sensitive to 
this phage. However, propagation of phage K on these less-sensitive strains resulted 
in all 14 being sensitive to the modified phage. Model in situ hand-wash studies using 
a phage-enriched wash solution resulted in a 100-fold reduction in staphylococcal 
numbers on human skin by comparison with numbers remaining after washing in 
phage-free solution. Infusion of the phage into a non-immunogenic bismuth-based 
cream resulted in strong anti-Staphylococcus activity from the cream on agar plates 
and broth assays. 
 
Results 
Phage K inhibits recently emerged drug resistant bacteria 
To test the host range and potency of phage K (Fig. 5) bacterial challenge 
experiments were performed.  Details of the bacterial strains are shown in Table 2.  
These include an S. aureus type strain, 36 human MRSA strains, 4 glycopeptide 
resistant strains, 4 distinct clinical isolates from bovine mastitis and 8 coagulase-
negative non-S. aureus species of Staphylococcus.  The MRSA strains have 
previously been shown by motif-dependant PCR to be distinct (M. Daly, personal 
communication; (Cotter et al. 1998). Of the 53 strains, 39 were successfully lysed by 
phage K as indicated by phage spot test and confirmed by plaque assay (Table 2). 14 
of the strains from the MRSA group were relatively insensitive to phage K in the 
initial challenge (Table 2).  Plaque formation did not occur with any of these when 
phage K was used, although there was inhibition in the lawn of bacterial growth, 
typically at phage concentrations of 108, 107 and 106 PFU/ml by using the plaque 
assay technique. This inhibition of growth in the lower dilutions occurred with all the 
apparently insensitive MRSA strains.  When phage K was incubated with these strains 
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in broth, modified phage K variants, which were capable of forming clear plaques on 
their respective hosts could be obtained for all of the 14 insensitive strains (Table 2).  
In addition, two of the modified phage, namely phage K.W64352 and phage 
K.W65216 were assayed for their ability to lyse or cross-react with all the other phage 
insensitive strains in the study. Where phage K.W64352 was used, normal plaque 
formation was evident on the majority of strains, but notably, plaques were pinpoint 
on strains W65216, M249180, 254959 and M251955, but the plaque numbers (EOP) 
were similar to those obtained on strain DPC5246. These pinpoint plaques suggest 
that these strains may have phage resistance systems in addition to restriction 
modification (r/m), which only permit a relatively low burst size. Similarly, when 
phage K.W65216 was used, plaques were faint and pinpoint on strains W64352 
(propagating host for phage K.W64352), M249138, M255409 and W69939. As with 
phage K.W64352, efficiency of plaquing on these strains was similar to that on strain 
DPC5246. This indicates that r/m is the principal cause of the phage insensitivity in 
the 14 isolates. It also indicates that there is common specificity among the r/m 
systems harboured by these strains.  
 
Bacterial challenge experiments 
Challenge experiments were performed in BHI broth with MRSA strain 
DPC5645. This involved adding phage K to an exponential culture of DPC5645 at 
37°C. The potency of phage K is illustrated in this challenge experiment, within 30 
min phage K started to reduce bacterial numbers and within 2 h the phage had 
reduced the MRSA isolate (DPC5645) from 5.7 x 106 CFU/ml to an undetectable 
level.  Plate counts confirmed that there were no viable bacteria remaining in the BHI 
10 h after phage treatment indicating that no BIMs had formed during the challenge. 
Indeed, further plate counts 25 h after phage infection confirmed the absence of BIMs 
in this experiment.  The absence of BIMs from this experiment agreed with the results 
of plaque assay procedure to detect and enumerate BIMs, in that at a MOI of 1, BIM 
formation did not occur on plates.  
 
Inhibition of S. aureus on skin by phage wash. 
Phage K was assessed for its ability to reduce the numbers of MRSA on 
human skin using S. aureus DPC5246 as a test strain. These trials demonstrated that 
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washing in phage-free ringers solution was associated with a slight reduction in the 
number of challenge organisms. When phage K was included in the wash at a titre of 
1.4 x 108 PFU/ml, the number of staphylococci remaining was reduced a further 100-
fold (Fig. 5).   
 
Phage inhibition of S. aureus in a bismuth-based cream.  
Phage K also exhibited inhibition of the indicator strain DPC5246 in a 
bismuth-based cream. The phage cream was placed in the centre of an overlaid plate 
with the indicator strain DPC5246. A zone of inhibition is seen surrounding the phage 
cream (Fig. 7A), which shows that the cream containing phage has killed the 
surrounding bacteria by bacterolysis. Importantly, the phage cream was also shown to 
kill the indicator strain when placed in broth cultures of the challenge organism. 
Following a 4 h incubation at 37°C, the control sample contained 8 x 107 CFU/ml of 
DPC5246 (turbid Fig. 7B, i) whereas no viable bacteria were detected in the test 
sample (clear Fig. 7B, ii), showing complete kill by the phage cream within 4 h.  
 
Discussion and Conclusions 
In this study we demonstrate that phage K inhibits 9 different species of 
Staphylococcus, namely, S. aureus, S. epidermidis, S. saprophyticus, S. chromogenes, 
S. captis, S. hominis, S. haemolyticus, S. caprea and S. hyicus. Within S. aureus, it is 
inhibitory to a wide range of distinct strains from different hospital and veterinary 
sources which were isolated over the last 3 years. We feel that these strains are 
representative of the problematic strains presently associated with infections in 
Ireland. Of particular interest is the inhibitory effect on recently emerged methicillin-
resistant strains (obtained from hospital staff, out-patients and in-patients). These 
studies show that phage K could be modified to inhibit less-sensitive strains, 
especially MRSA, with better efficiency strains simply by passing the phage through 
the target strain, which ordinarily would not allow plaque formation. These data 
suggests the presence of restriction modification activity in these MRSA isolates and 
also that there is a large degree of common specificity among the r/m systems 
harboured by these strains. The modified phage generated in this study could be 
combined with phage K in a cocktail to increase the host-range of the phage 
preparation. The bacterial challenge using phage K indicated that no bacteria 
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remained 2 h after phage addition in cases where up to 107 CFU/ml were used. It is 
apparent from the results that washing hands in the presence of phage K has the 
potential to significantly reduce the numbers of problematic S. aureus strains that are 
resident on human hands.  With regard to the inclusion of phage in the cream, its anti-
bacterial effect is self-evident from the in-vitro experiment described.  This suggests 
that such phage creams could find applications in treatment of local skin infections.   
In this study we demonstrate that the exclusively lytic phage K (25) has particular 
applications in the prevention and/or treatment of infections caused by antibiotic-
resistant staphylococci. In this respect, we have shown its ability to kill a broad range 
of newly isolated pathogenic staphylococci including both human and veterinary 
strains. Moreover, the study details some preliminary findings, which show the 
potential of delivering the phage in an anti-staphylococcal cream or hand wash. 
 
4. Genome of staphylococcal phage K: a new lineage of Myoviridae infecting 
low G+C content Gram positive bacteria. 
 
Summary 
Phage K is a polyvalent phage of the Myoviridae family which is active 
against a wide range of staphylococci.  Phage genome sequencing revealed a linear 
DNA genome of 127,395 base pairs, which encodes 118 putative open reading 
frames.  The genome is organised in a modular form, encoding modules for lysis, 
structural proteins, DNA replication and transcription.  Interestingly, the structural 
module shows high homology to the structural module from Listeria phage A511, 
suggestive of intergenus horizontal transfer.  In addition, phage K exhibits the 
potential to encode proteins necessary for its own replisome, including DNA ligase, 
primase, helicase, polymerase, RNase H and DNA binding proteins.  Phage K has a 
complete absence of GATC sites making it insensitive to restriction enzymes which 
cleave this sequence.  Three introns (lys-I1, pol-I2 and pol-I3) encoding putative 
endonucleases were located in the genome.  Two of these (pol-I2 and pol-I3) were 
found to interrupt the DNA polymerase gene while another (lys-I1) interrupts the lysin 
gene.  Two of the introns encode putative proteins with homology to HNH 
endonucleases, whereas the other encodes a 270 aa protein, which contains two zinc 
fingers (CX2CX22CX2C and CX2CX23CX2C).  The availability of the genome of this 
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highly virulent phage, which is active against infective staphylococci, should provide 
new insights into the biology and evolution of large broad-spectrum polyvalent phage. 
 
Results and Discussion 
General features of the genome of phage K  
The phage K genome is presented as a 127,395 bp contiguous sequence of 
linear double-stranded DNA which encodes at least 118 putative ORFs, which were 
capable of encoding peptides of at least 100 amino acids in all six reading frames 
preceded by a potential Shine-Dalgarno sequence at a distance of at least 3-18 bp 
from a start codon (AUG, GUG or UUG) (Table 3).  The majority of ORFs (112) 
initiate translation with the AUG start codon, whereas only 5 (ORFs 38, 40, 41, 42 
and 96) initiate translation with the UUG start codon and 1 (ORF 63) initiates with a 
GUG start codon (Table 3).  Bioinformatic analysis of ORFs revealed that the 
majority exhibited low identities with proteins from the database (Table 3), which 
often is the case with new genomes.  The genome can be divided into two distinct 
regions, which are divergently transcribed as indicated by bioinformatic analysis.  In 
this respect, of the 118 ORFs, 85 are transcribed in one orientation with 33 in the 
opposite, with all of the latter grouped together in the first 30 kb as illustrated in Fig. 
8.  Phage K has a G + C content of 30.6% which is significantly lower than that 
generally associated with the staphylococcal bacterial genome.  
 
Phage K has its genes arranged in modules  
Temperate staphylococcal phage are generally organised in a modular form 
which include modules for lysogeny, DNA replication, transcriptional regulation, 
packaging, structural proteins and lysis.  The organisation of these temperate 
staphylococcal phage genomes is similar to those of temperate streptococcal phage. 
Phage K also appears to have its genes arranged in modules but the order differs from 
the temperate phage and the two sequenced lytic phage which have their lysis module 
embedded in the structural region.  The modules of phage K are not as well defined as 
those of the temperate staphylococcal and streptococcal phage; for example, there is a 
lack of intergenic regions between the structural and DNA replication and 
transcription modules.  Putative rho-independent terminators were identified (Table 2) 
using the TransTerm program (Ermolaeva et al. 2000).  Three further terminators 
were located upstream of ORFs 1, 56 and 118 on the divergent strand to the ORFs.  
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These terminators are characterised by a stem loop in the mRNA followed by a U-rich 
sequence and allow for a punctuation of the 3’ ends of multi-cistronic mRNA.   
 
Taxonomy and comparative genomics 
The need for a genome based taxomony tree has recently been identified 
(Rohwer and Edwards 2002).  After studying 3,981 proteins of 105 genomes no single 
gene that could be used as a basis for a classification system was found in all phages.  
Instead a taxonomic system was based on a predicted phage proteome.  The current 
phage proteome taxonomy is based on both complete phage genomes and prophage 
identified from within bacterial genomes (Casjens 2003).  The database consists of 
16,260 proteins from 375 genomes.  The ICTV family Myoviridae grouped together 
in their system with the exception of T4 and P4 coliphage.  These two phage represent 
their own groups in the proteomic tree indicating that they are the only sequenced 
representatives.  Likewise, phage K does not fall within a defined group, confirming 
that it is the founding member of a new taxonomic group, and that the Myoviridae are 
more diverse than their visual characterisations suggest. 
 
Lysis module is located in the first divergently transcribed 30 kb 
The lysis module (ORFs 30 to 33) is located at the end of the first 30 kb where 
all ORFs are divergently transcribed in relation to the rest of the genome (Fig. 8). 
ORF 33 encodes a putative holin of 167 aa (18.1 kDa) whose stop codon overlaps by 
1 bp in a different reading frame ORF 32.  Both ORFs 33 and 32 have recognisable 
ribosome binding sites (Table 3).  The putative holin of phage K exhibited 61% 
identity with a holin from phage Twort (Table 3) and probably functions by 
generating pores in the bacterial cell membrane.  The lysin (spliced products of ORFs 
30 and 32, see below) contains the recently described CHAP domain which is 
characterised by three conserved motifs (Bateman and Rawlings 2003; Rigden et al. 
2003).   
 
Introns with ORFs interrupting genes with crucial enzymatic functions 
Analysis of the genome revealed that both the putative polymerase and lysin 
genetic determinants contained intron-like sequences.  Indeed, the polymerase gene 
contained two such putative structures (pol-I2 and pol-I3), each encoding 
endonucleases (ORF 87 [I-KsaII] and ORF 89 [I-KsaIII], respectively) (Fig. 9A).  In 
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contrast, the lysin gene contained one intron like sequence (lys-I1), which also 
encodes a distinct endonuclease (ORF 31 [I-KsaI]) (Fig. 9B).  Both I-KsaI and I-
KsaIII exhibit homology to HNH endonucleases (Table 1) and contain a HNH motif. 
Interestingly I-KsaI also contains an intron-encoded nuclease repeat motif at the C-
terminal end (data not shown).  The functions of the nuclease repeats are unknown but 
could be involved in DNA binding via the helix-turn-helix motif (residues 116 to 
164).  I-KsaII exhibited no significant homology to any protein in the database.  
Closer examination of I-KsaII revealed the existence of two potential zinc-binding 
motifs (CX2CX23CX2C and CX2C22CX2C) and thus it may belong to a subfamily of 
HNH endonucleases containing a zinc-binding motif.  
 
Overview of relationship to other phage: phage K and Listeria phage A511 have 
similar structural modules. 
When structural proteins of phage K were examined by SDS-PAGE (Fig. 10), 
four were identified that correspond to predicted proteins of phage K (ORF 44, 49, 50 
and 95), on the basis of N-terminal sequencing.  N-terminal sequencing identified the 
putative major tail sheath protein ORF 49 of phage K which is 54.5 kDa (Fig. 10).  
The amino acid sequence matched the first 7 N-terminal amino acids of ORF 49 
except for the initial methionine.    Database searches revealed a 57% identity with the 
tail sheath protein of Listeria phage A511 (Fig. 10), which is a member of the 
Myoviridae family, has a contractile tail, linear double-stranded DNA, and a large 
genome of 116 kb (Loessner and Scherer 1995).  Only its structural module and 
amidase have been sequenced to date, and it cannot, therefore, be included on the 
proteome tree.  N-terminal sequencing of band B resulted in 15 amino acids which are 
identical to residues 25 to 39 of the deduced protein product of ORF 44, indicating 
postranslational cleavage of the first 23 amino acids.  This ORF shares 82% identity 
with the capsid protein of phage Twort (Table 3).  ORF 44 shares 66% identity with 
the capsid protein of phage A511 which also exhibits postranslational cleavage of the 
first 23 amino acids (Loessner and Scherer 1995) (Fig. 10).  Interestingly band C 
corresponds to a protein of unknown function (ORF 95) (Fig. 10).  N-terminal 
sequencing revealed the first 17 amino acids of this protein, which has a predicted 
molecular mass of 23.2 kDa (Fig. 10).  The amino acid sequence obtained from band 
D (Fig. 10) corresponds to ORF 50 with a predicted molecular mass of 15.9 kDa.  
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ORF 50 shares an identity of 68 % with ORF 8 from Listeria phage A511 which has 
an unknown function (Loessner and Scherer 1995).  
The proteins within the structural module are not homologous to the 
equivalent proteins of the sequenced lytic and temperate staphylococcal phage but 
they do exhibit homology to Listera phage A511, with the exception of ORF 41.  
Interestingly this 11,361 bp (minus the portal protein) structural region of phage K 
shows significant homology with phage A511 not just at gene level but also in the 
arrangement of ORFs (Loessner and Scherer 1995) (Fig. 11).  The dramatic similarity 
between this large (11 kb) region of both phage would suggest that phage K and A511 
are related and could constitute a new lineage of Myoviridae infecting low-G+C 
gram-positive bacteria.  The elucidation of the genome of A5ll and other large 




Phage K is a large, virulent bacteriophage, which infects a broad range of 
staphylococci including multiple drug resistant strains of S. aureus.  Detailed genetic 
characterisation of this phage has unveiled a number of features as follows. (i) Phage 
K has been taxonomically placed in its own group because of overall uniqueness 
when compared to other phage. (ii) The genome also contains introns in essential 
phage functions, two in the polymerase and one in the lysin genes. (iii) Phage K 
contains a large region with remarkable homology to Listeria phage A511. (iv) 
Finally, phage K has a remarkable paucity of GATC and GGNCC, sites suggesting 




The resurgence in the study of bacteriophage as potential therapeutics is 
clearly evident given both the increased number of publications on the subject and the 
commercial interest devoted to them, including the setting up of a numbebr of small 
companies.  In this respect, phage may prove to have an important role to play in 
killing pathogens such as S. aureus, a major cause of infections in humans and 
animals.  In this study, three different phage were investigated for their potential as 
anti-bacterial agents against S. aureus.  Two of these, CS1 and DW2 were isolated as 
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part of this study and the third, phage K was purchased from a culture collection.  
Phage K was the most potent of the three phage since it could kill MRSA strains, 
coagulase negative staphylococci and mastitic causing S. aureus strains compared to 
CS1 and DW2, which were specific for S. aureus bovine mastitis-causing strains.  No 
local immune response was observed in the bovine udder, suggesting that the phage 
cocktail could be safely applied and tolerated via this route.  Subsequently, the ability 
of phage K to replicate in raw milk was studied with a view to developing anti-
mastitis applications.  Surprisingly, we found that raw milk inhibited phage K 
proliferation, while heat-treated milk supported phage K infection and multiplication.  
This inhibition is possibly due to the clumping state of the cells caused by 
immunoglobulins.  We feel that this observation has important ramifications for 
mastitis applications of phage therapy.   
While phage therapy shows tremendous potential for treatment of 
staphylococcal infections, it is fair to say that there is an urgent need for scientifically 
conducted double blind placebo-controlled trials to prove efficacy.  Although phage 
may not replace antibiotics in clinical practice, they may find their own niche in the 
treatment of certain infections, which are difficult to treat with antibiotics.  
Furthermore, the use of new technologies and molecular techniques allows the 
screening of phage genomes for additional anti-bacterials and new drug discovery 
targets (Liu et al. 2004).  In this respect it is interesting that the genome of phage K 
encodes up to 200 genes of which approximately only 30% are homologous to protein 
sequences in the database.  Compare this situation to bacterial genomics where it is 
common to find that greater than 70% of the predicted proteins have known 
homologues.  This alone demonstrates how much we have to learn about the biology 
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S. aureus strain 
 






DPC5245 Bovine RAPD 5, DPC Culture Collection + + + 
DPC5246 Bovine RAPD 7, DPC Culture Collection + + + 
DPC5247 Bovine RAPD 4, DPC Culture Collection + + + 
W64352 MRSA, CIT culture collection (2001) - - + 
M249318  MRSA, CIT culture collection (2001) + + + 
M255039 MRSA, Waterford Regional Hospital (2001) - + + 
MS 811 MRSA, Cork University Hospital (2003) + - + 
89715 MRSA, Cork University Hospital (1999) + + + 
+ susceptible to phage by spot test 
- not susceptible to phage by spot test 
MRSA: Methicillin Resistant S. aureus 
CIT: Cork Institute of Technology 
DPC: Dairy Products Research Centre 

































Table 1: Host range of phages CS1 and DW2 compared to phage K 
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a Public Health Laboratory Service. b Cork University Hospital, Cork, Ireland. c Waterford Regional 
Hospital, Waterford, Ireland. d Dairy Products Center, Fermoy, County Cork, Ireland. 
e Coagulase negative. f Spot assay results. +, phage sensitive; -, not phage sensitive. g EOP, efficiency 
of plaquing; NC, not countable (plaques are too small to count, but confluent lysis occurs at >107 
PFU/ml). h Sensitivity to methicillin at 5 µg/ml. S, sensitive; R, resistant. i VRSA, vancomycin-
resistant S. aureus; hVRSA, heterogeneous vancomycin-resistant S. aureus. 










S. aureus 8325 Type straina S + nc   
S. aureus St3550 Teicoplanin resistanta S + 0.087   
S. aureus St2573 Teicoplanin resistanta R + 0.11   
S. aureus Mu50 VRSAa R + nc   
S. aureus Mu3 hVRSAa R + nc   
S. aureus M249318 Human MRSAb R -  + 6.75 x 10-5 
S. aureus W64352 Human MRSAb R -  + 2.3 x 10-1 
S. aureus W65216 Human MRSAb R -  + 2.8 x 10-4 
S. aureus M231003 Human MRSAb R + 1.03 x 10-1   
S. aureus M249180 Human MRSAb R -  + 1.09 x 10-3 
S. aureus MS811 Human MRSAb R -  + 2.26 x 10-3 
S. aureus DPC5646 Human MRSAb R + 0.77   
S. aureus DPC5645 Human MRSAb R + 0.45   
S. aureus DPC5647 Human MRSAb R + 8.46 x 10-7   
S. aureus M249954 Human MRSAc R + 1.12 x 10-1   
S. aureus M250594 Human MRSAc R + 3.23 x 10-1   
S. aureus M254959 Human MRSAc R -  + 7.33 x 10-5 
S. aureus M255039 Human MRSAc R -  + 1 
S. aureus M255409 Human MRSAc R -  + 7.6 x 10-2 
S. aureus M253472 Human MRSAc R + 1   
S. aureus M249739 Human MRSAc R + 1.57 x 10-1   
S. aureus M249892 Human MRSAc R + 4.10 x 10-1   
S. aureus M252776 Human MRSAc R + 1   
S. aureus M251760 Human MRSAc R + 1.32 x 10-1   
S. aureus W71683 Human MRSAc R + 5.89 x 10-2   
S. aureus M253206 Human MRSAc R + 8.57 x 10-2   
S. aureus W73365 Human MRSAc R -  + 3.4 x 10-1 
S. aureus M253470 Human MRSAc R + 6.93 x 10-1   
S. aureus M249025 Human MRSAc R + 1.41 x 10-1   
S. aureus M249138 Human MRSAc R + 1   
S. aureus M249807 Human MRSAc R + 1.48 x 10-1   
S. aureus M250108 Human MRSAc R + 7.3 x 10-1   
S. aureus M249671 Human MRSAc R -  + 1.46 x 10-4 
S. aureus W69939 Human MRSAc R -  + 1.177 x 10-3 
S. aureus M253164 Human MRSAc R -  + 2.65 x 10-2 
S. aureus M249678 Human MRSAc R -  + 1.75 x 10-4 
S. aureus M251955 Human MRSAc R -  + 2.1 x 10-1 
S. aureus M250564 Human MRSAc R + 5.1 x 10-3   
S. aureus MM77438 Human MRSAc R + 2.76x10-2   
S. aureus MM257671 Human MRSAc R + 5.46 x 10-3   
S. aureus MM234150 Human MRSAc R + 6.2 x 10-1   
S. aureus DPC5245 Bovined S + 1   
S. aureus DPC5246 Bovined S + 1   
S. aureus DPC5247 Bovined S + 1   
S. aureus DPC5971 Bovined S + 0.21   
S. epidermidis DPC6010 e Bovined S + 0.46   
S. saprophyticus DPC6011 e Bovined S + 0.025   
S. chromogenes DPC6012 e Bovined S + 0.16   
S. captis DPC6013 e Bovined S + nc   
S. hominis DPC6014 e Bovined S + 2.1 x 10-8   
S. haemolyticus DPC6015 e Bovined S + nc   
S. caprea DPC6016 e Bovined S + 0.022   
S. hyicus DPC6017 e Bovined S + 0.087   
















1* 2934 2449 18.4 Hypothetical protein    
2* 3358 2927 16.7 Hypothetical protein    
3 3914 3372 21.5 Hypothetical protein    
4* 4414 19.5 Pseudomonas aeruginosa, conserved hypothetical protein 3e-24 39 (40) NP_253270 
5* 4825 4427 16.1 Hypothetical protein    
6* 5529 4822 27.7 Agrobacterium tumefaciens, serine/threonine protein phosphatase I 2e-13 29 (26) NP_534038 
7*‡ 6183 5629 21.2 Hypothetical protein    
8*‡ 8050 7502 21.9 Hypothetical protein    
9* 9194 8457 28.7 Hypothetical protein    
10* 10003 9614 15.2 Hypothetical protein    
11*‡ 10798 10316 18.8 Hypothetical protein    
12*‡ 11390 10848 20.4 Hypothetical protein    
13* 11923 11390 20.7 Hypothetical protein    
14* 13213 12368 31.7 Hypothetical protein    
15* 13809 13225 21.9 Mycoplasma penetrans, AAA family ATPase 5e-20 40 (32) NP_757966 
16* 15233 14817 16 Hypothetical protein    
17*‡ 15669 15367 11.3 Enterococcus hirae, ArpR 6e-18 45 (45) CAA90708 
18* 18110 16062 79.8 Enterococcus faecalis, plasmid pAD1, unknown protein 3e-04 28 (6) AAL59463 
19*‡ 19226 18648 21.4 Hypothetical protein    
20* 19845 19219 23.8 Hypothetical protein    
21* 20734 19838 35 Clostridium acetobutylicum, homolog of eukaryotic DNA ligase III 3e-05 27 (14) NP_347388 
22* 21767 21027 28.6 Neisseria meningitidis, PhoH-related protein 1e-14 36 (38) NP_273886 
23* 22433 21819 23 Staphylococcus aureus, temperate phage phiSLT, orf636 0.51 26 (18) NP_075517 
24* 22874 22449 15.8 Clostridium perfringens, Ribonuclease H1 7e-14 34 (34) NP_562366 
25* 23719 23078 24.6 Hypothetical protein    
26*‡ 24971 24279 24.8 Staphylococcus aureus, hypothetical protein 7e-07 29 (25) NP_372619 
27* 25793 25158 24.8 Streptococcus pyogenes, hypothetical phage protein 2e-22 36 (37) NP_607354 
28*‡ 26651 25860 29.3 Synechocystis sp., unknown protein 1e-15 24 (20) NP_440390 
29* 26959 26651 12.2 Hypothetical protein    
30‡ 27701 27072 23.1 Staphylococcus aureus, Autolysin (N-acetylmuramoyl-L-alanine amidase) 1e-54 52 (52) P24556 
31* 28472 27972 19.2 Bacteroides thetaiotaomicron, endonuclease 1e-12 39 (33) NP_810939 
32* 29435 28632 29.8 Staphylococcus aureus, phage Twort, N-acetylmuramoyl-L-alanine 
amidase 
1e-38 40 (37) CAA69021 
33* 29938 29435 18.1 Staphylococcus aureus, phage Twort,  holTW (holin) 9e-38 61 (53) CAA69020 
34* 34507 34833 12.3 Hypothetical protein    
35* 34848 36665 70.2 Ralstonia solanacearum, probale bacteriophage-related protein 0.002 25 (8) NP_518974 
36* 36658 37479 30.7 Hypothetical protein    
37*‡ 37636 38115 18.5 Hypothetical protein    
38*†‡ 38157 39350 43.6 Bacillus cereus, cell surface protein 3e-05 28 (24) NP_346725 
39* 39435 39776 12.8 Hypothetical protein    
40† 39794 40165 14.5 Hypothetical protein    
41*†‡ 40169 41860 64.0 Escherichia coli, bacteriophage P27, putative portal protein 0.004 22 (10) NP_543090 
42*† 42054 42827 28.6 Listeria monocytogenes, bacteriophage A511, orf 1 2e-62 54 (63) CAA62538 
43* 42846 43796 35.7 Hypothetical protein    
44‡ 43912 45303 51.2 Staphylococcus aureus, phage twort capsid protein 0.0 82 (81) AAQ6728 
    Listeria monocytogenes, bacteriophage A511, major capsid protein e-174 66 (67) CAA62540 
45* 45704 46612 31.2 Listeria monocytogenes, bacteriophage A511, orf 3 e-104 60 (36) CAA62541 
46* 46626 47504 33.7 Listeria monocytogenes, bacteriophage A511, orf 4 8e-56 26 (9) CAA62542 
47* 47504 48124 23.8 Listeria monocytogenes, bacteriophage A511, orf 5 2e-25 46 (35) CAA62543 
48* 48143 48979 31.8 Listeria monocytogenes, bacteriophage A511, orf 6 6e-53 38 (39) CAA62544 
49* 49223 50986 54.5 Listeria monocytogenes, bacteriophage A511, major tail sheath protein 0.0 57 (58) CAA62546 
50*‡ 51059 51487 15.9 Staphylococcus aureus, phage twort,  unknown 3e-62 85 (84) AF132670 
    Listeria monocytogenes, bacteriophage A511, orf 8 5e-48 68 (67) CAA62547 
51* 51767 52225 18.1 Hypothetical protein    
52* 52514 52825 12.3 Hypothetical protein    
53* 52957 53415 18.1 Listeria monocytogenes, bacteriophage A511, orf 9 1e-23 39 (39) CAA62548 
54*‡ 53459 53995 20.9 Hypothetical protein    
55 54051 58106 144 Lactococcus lactis, bacteiophage CP-1,  orf 18 4e-08 32 (3) NP_047298 
56 58185 60611 91.2 Staphylococcus epidermidis, secretory antigen SsaA-like protein 4e-32 49 (13) NP_765044 
57* 60625 61512 34.6 Hypothetical protein    
58* 61512 64058 96.1 Bacillus subtilis, glycerophosphoryl diester phosphodiesterase 1e-41 38 (11) NP_388095 
59* 64165 64956 29.3 Hypothetical protein    
60* 64956 65480 20 Hypothetical protein    
Table 3. General features of putative ORFs from phage K with best matches in the database. 
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61* 65480 66184 26.6 Salmonella typhi., putative bacteriophage baseplate protein 0.020 45 (7) NP_456045 
62 66199 67245 39.2 Clostridium tetani, phage-like element pbsx protein xkdT  5e-06 24 (43) NP_782676 
63† 67266 70325 116.2 Hypothetical protein    
64 70436 70957 19.2 Hypothetical protein    
65*‡ 70978 74436 129 Dichelobacter nodosus, vrlC protein 9e-33 27 (10) T17382 
66* 74644 76566 72.5 Staphylococcus aureus, SLT orf 488-like protein 0.021 29 (4) AAL82326 
67* 76589 76963 14.6 Hypothetical protein    
68*‡ 76970 78346 50.4 Listeria monocytogenes, lmo1188 0.034 24 (8) NP_464713 
69* 78438 80186 37.2 Salmonella typhi., putative helicase 2e-36 33 (16) NP_569550 
70* 80198 81811 63.2 Enterococcus faecalis, putative Rep protein 0.031 40 (5) CAC29157 
71* 81804 83246 54.6 Salmonella typhi., putative DNA helicase 4e-11 21 (15) NP_569513 
72 83325 84362 40.1 Listeria monocytogenes, similar to putative exonucleases SbcD 1e-09 23 (19) NP_465171 
73* 84362 84739 14.9 Hypothetical protein    
74* 84739 86658 73.4 Yersinia pestis, plasmid pMT1, probable exonuclease 2e-21 34 (9) T14925 
75* 86658 87254 23.2 Hypothetical protein    
76* 87269 88336 40.9 Helicobacter pylori, DNA primase 5e-07 24 (17) NP_206814 
77* 88741 89193 17 Hypothetical protein    
78 89180 89788 23.6 Bacteriophage T5, D14 protein 1e-05 26 (17) O48499 
79* 89805 90197 14.7 Staphylococcus epidermidis, NrdI protein 3e-13 35 (50) NP_764067 
80 90212 92326 80.2 Staphylococcus aureus, phage Twort, large ribonucleotide reductase 
subunit 
0.0 72 (73) AAM00816 
81 92340 93389 40.4 Staphylococcus aureus, ribonucleoside reductase minor subunit 3e-84 53 (48) NP_371256 
82* 93407 93736 12.4 Hypothetical protein    
83 93720 94040 12 Alicyclobacillus acidocaldarius, Thioredoxin 0.013 33 (31) P80579 
84 94247 94843 23.5 Hypothetical protein    
85*‡ 94853 95158 11.9 Chlamydophila pneumoniae,  Integration Host Factor Alpha 0.003 26 (26) NP_224616 
86* 95234 96106 33.2 Bacillus subtilis, Bacteriophage SPO1, DNA polymerase 0.054 25 (12) P30314 
87* 96314 96784 18.6 Hypothetical protein     
88 96920 98263 52.8 Thermotoga maritima, DNA-directed DNA polymerase I 1e-06 22 (13) NP_229419 
89 98429 99238 31.2 Bacteriophage Bastille, HNH endonuclease, I-BasI 6e-22 40 (40) AAO93095 
90 99472 100332 32.9 Bacillus subtilis, phage SPO1, DNA -directed DNA polymerase 2e-31 36 (31) JC1269 
91* 100660 101142 18.9 Hypothetical protein    
92*‡ 101229 102500 46.9 Hypothetical protein    
93* 102560 103816 46.8 Thermotoga maritima, DNA repair protein 2e-27 30 (24) NP_229655 
94* 104160 104822 26.6 Bacillus subtilis, Bacteriophage SPO1,RNA Pol sigma GP34 Factor 3e-05 32 (17) P06227 
95* 104950 105582 23.2 Hypothetical protein    
96*‡ 105605 106117 17.8 Staphylococcus aureus, temperate phage phiSLT, major tail protein 4e-14 40 (49) NP_075510 
97* 106719 107474 29.2 Hypothetical protein    
98 107467 108717 47.5 Hypothetical protein    
99 108731 109099 14 Hypothetical protein    
100*‡ 109086 109397 12 Hypothetical protein    
101* 109990 110757 30 Staphylococcus aureus, hypothetical protein 0.001 36 (16) CAB60746 
102* 110735 111181 17.3 Hypothetical protein    
103* 112416 113147 28.4 Hypothetical protein    
104* 113165 113623 17.9 Hypothetical protein    
105* 113688 114131 17.5 Hypothetical protein    
106*‡ 114148 114852 27.4 Hypothetical protein    
107*‡ 114914 115312 15.4 Hypothetical protein    
108*‡ 115706 116176 17.9 Hypothetical protein    
109* 117041 117349 12 Hypothetical protein    
110* 117346 118254 35.2 Pyrococcus horikoshii, ribose-phosphate pyrophosphokinase 8e-09 27 (24) NP_143754 
111*‡ 118272 119741 56.1 Haemophilus ducreyi, putative nicotinamide phosphoribosyl transferase e-141 52 (52) AAK06405 
112* 120082 120477 15.5 Hypothetical protein    
113 121090 121401 11.7 Hypothetical protein    
114* 121407 121706 11.6 Hypothetical protein    
115* 122253 122606 13.9 Hypothetical protein    
116* 122625 123011 15.6 Hypothetical protein    
117* 124587 124913 12.7 Hypothetical protein    
118* 125811 126158 13.7 Hypothetical protein    
        
†, non AUG start codons 
‡, presence of putative rho-independent terminators downstream of the ORF 













(a) Electron micrographs of phage CS1 and DW2. Phage were negatively stained with 
1% uranyl acetate. (i) phage CS1, (ii) phage DW2. Scale bar represents 50 nm. (b) 
Phage DNAs digested with restriction endonucleases. Lane identification is as 
follows: 1, Xba1 digest of phage K; 2 and 4 Xba1 digest of CS1; 3, Xba1 digest of 
DW2, 5, Xho1 digest of phage K; 6 and 8 Xho1 digest of phage CS1 and 7, Xho1 
digest of phage DW2.  Lanes marked i, ii and iii contain 1 kb ladder, lambda HindIII 
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Bacterial challenge experiment in vitro against S. aureus DPC5246. Comparison of 
phage CS1, DW2, both in combination and a phage cocktail of phage CS1, DW2 and 
K to lyse the indicator strain S. aureus DPC5246. Challenge test was carried out at 
37°C. Time of phage addition is indicated by an arrow. Phage and phage 



















Figure 3  
Challenge with phage K against S. aureus DPC5645 at 37°C in (a) BHI; (b) HT milk; 
(c) raw milk; (d) DCS. In each case phage K was added to S. aureus DPC5645 when 
the culture had reached a titre of approximately 107 CFU ml-1. ○ DPC5645 without 
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Confocal Scanning Laser Microscopy (CLSM) micrographs of raw milk and HT milk 
containing S. aureus DPC5246 stained with LIVE/DEAD Baclight viability stain. 
Live cells have stained green and dead cells red. (a) S. aureus DPC5246 in raw milk; 
(b) S. aureus DPC5246 in raw milk challenged with phage K; (c) S. aureus DPC5246 
in HT milk; (d) S. aureus DPC5246 in HT milk challenged with phage K. 


























Electron micrograph images of phage K negatively stained with 1% uranyl acetate. 




























Graph of phage K hand wash challenge against Staphylococcus aureus DPC5246. 
Black bar, bacterial numbers in the original suspension; grey bar, unwashed control; 
white bar, washed control (washed with Ringers containing no phage); hatched bar, 












































Figure 7  
Activity of phage cream. (A) Activity of cream on an agar plate overlaid with the 
indicator strain DPC5246. (B) Activity of phage cream in BHI broth. (i) Control broth 







































Figure 8.   
ORF organisation of Phage K.  ORFs 1 to 118 are indicated by arrows; the numbering 
corresponds to that in Table 1.  Blue arrows, putative lysis module; red arrows, the 
structural module; green arrows, DNA replication and transcription module; grey 
arrows, proteins with a putative function; black arrows, hypothetical proteins.  Arrows 
with black vertical lines indicate three intron-carried ORFs.  Arrows are roughly 
drawn to scale.  Vertical lines mark two putative promoters.  L and R, direction of 
transcription (left or right). Start codons and ribosome binding sites are indicated in 
boldface and putative – 10 and – 35 sites are underlined.  Dashed vertical lines 
represent the position of four putative tRNAs. 
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Figure 9.   
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(A) Schematic representation of phage K polymerase gene interrupted by intron DNA.  Dashed lines 
represent intron pol-I2 and pol-I3, encoding I-KasII and I-KasIII’ respectively.  The in vivo splicing of 
phage K intron DNA from the polymerase gene is illustrated on a 1 % agarose gel.  Lane 1, PCR 
product obtained on phage K DNA using primers PolF and PolR; lane 2, PCR product obtained from 
cDNA of phage K using primers PolF and PolR; lane 3,1 kb ladder (New England Biolabs).  Sizes of 
PCR products are indicated on the right in base pairs.  The schematic diagram is overlaid with a graph 
illustrating the % G+C content in this section of the genome.  (B) Schematic representation of phage K 
lysin gene interrupted by intron DNA.  Dashed lines represent intron lys-I1 encoding I-KasI. The in 
vivo splicing of phage K intron DNA from the lysin gene is illustrated on a 1 % agarose gel.  Lane 1, 
PCR product obtained on phage K DNA using primers LysF and LysR; lane 2 PCR product obtained 
from cDNA of phage K using primers LysF and LysR; lane 3, 1 kb ladder (New England Biolabs).  
Sizes of PCR products are indicated on the right in base pairs. The schematic diagram is overlaid with a 




Figure 10.   
One-dimensional SDS-PAGE of phage K proteins stained with Coomassie brilliant 
blue and schematic diagram of similarities with Listeria phage A511.  Bands A, B, C 
and D represent the four proteins that were N-terminal sequenced. The N-terminal 
sequences of each band and the ORF from the genome of phage K to which each band 
corresponds are shown to the right. Numbering of ORFs for phage A511 corresponds 
to that in reference 23.  Dark grey arrows represent ORFs with a corresponding ORF 
in each phage and light grey arrows represent ORFs that have no corresponding ORFs 
between phage K and A511.  Percent identities shared between ORFs of Phage K and 
A511 are indicated in boxes in the schematic diagram. 
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  15.9 kDa ASEAKQTVHTBand D
54 % 66 % 60 % 26 % 46 % 38 % 63 % 57 % 68 % 39 %
